Panacea Acquisition today filed an investor presentration on merger partner Nuvation Bio, which is focused on developing cancer treatments. The deal was announced in October.
In addition to the approximately $144 million held in Panacea’s trust (assuming no redemptions), a group of premier healthcare investors has committed to participate in concurrent equity financings totaling slightly more than $500 million at $10 per share. Read more.
Related Posts
Technology and Telecommunication Acquisition Hit with Nasdaq Delisting Notice
The SPAC raised $100 million in January 2022 to target telecomm and tech companies in Malaysia.
Ocean Drive Acquisition Files for $250M IPO
The new SPAC said it will focus on companies that provide technological solutions and innovation targeting the real estate industry.
Aesther Healthcare Acquisition Offers 27 Cents/Share for 6-Month Extension on Ocean Biomedical Deal
The SPAC has already pumped $1,050,000 into trust for the current extension that expires next month.
Isos Acquisition Closes Business Combination with Bowlero Following Shareholder Approval
Bowlero stock and warrants begin trading today on the NYSE.